INTT

inTEST is a small-cap test-and-measurement supplier whose fortunes track the highly cyclical semiconductor equipment market — management itself frames Semi as its largest and most volatile end-market, 'characterized by rapid technological change, competitive pricing pressures and cyclical market patterns,' and says orders and revenue 'can be erratic' quarter to quarter. That cyclicality is now working against it: FY2025 revenue fell 12.9% to $114M (off the FY2024 peak of $131M), gross profit dropped 11.7%, and the company swung to a $2.53M net loss and a -$3.73M operating loss from FY2024's $2.89M profit. Notably, profitability was already eroding before the revenue roll-over — net income collapsed from $9.34M (FY2023) to $2.89M (FY2024) even as revenue hit a record — so this is margin pressure compounded by a demand downturn, not a clean top-line miss.

What keeps this out of 'sell/avoid' territory is balance-sheet quality. Equity of $104M dwarfs total liabilities of $47.7M (0.46x liabilities/equity), long-term debt is a trivial $1.41M, current assets of $78.6M cover current liabilities of $35.8M by ~2.2x, and — critically — operating cash flow was positive at $7.32M (up 91.4%), comfortably above net income because $6.8M of D&A is a non-cash drag on GAAP earnings. The loss is real but the company is not burning cash or financially stressed, and it kept investing (R&D +10.4%, still funding market diversification away from Semi dependence). This is a down-cycle, not a distress story.